Cochrane review: Recombinant growth hormone for idiopathic short stature in children and adolescents

摘要

Background nIdiopathic short stature (ISS) refers to children who are very short compared with their peers for unknown or hereditary reasons. Recombinant human growth hormone (GH) has been used to increase growth and final height in children with ISS. nnObjectives nTo assess the effects of recombinant human GH on short-term growth and final height in children with ISS. nnSearch strategy nStudies were obtained from computerised searches of MEDLINE, EMBASE, The Cochrane Library, Science Citation Index, BIOSIS and Current Controlled Trials. Article reference lists were assessed for trials and experts and pharmaceutical companies were contacted. nnSelection criteria nRandomised controlled trials were included if they were carried out in children with ISS with normal GH secretion. GH had to be administered for a minimum of six months and be compared with placebo or no treatment. A growth or height outcome measure had to be assessed.